Thrivent Financial for Lutherans Makes New Investment in Precision BioSciences Inc (NASDAQ:DTIL)

Thrivent Financial for Lutherans bought a new stake in Precision BioSciences Inc (NASDAQ:DTIL) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 47,013 shares of the company’s stock, valued at approximately $284,000. Thrivent Financial for Lutherans owned 0.09% of Precision BioSciences at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. New York State Common Retirement Fund boosted its stake in shares of Precision BioSciences by 247.3% during the 4th quarter. New York State Common Retirement Fund now owns 32,300 shares of the company’s stock worth $449,000 after purchasing an additional 23,000 shares during the period. Rhumbline Advisers bought a new stake in Precision BioSciences in the fourth quarter worth about $476,000. State Street Corp boosted its position in shares of Precision BioSciences by 289.1% during the fourth quarter. State Street Corp now owns 554,627 shares of the company’s stock valued at $7,704,000 after buying an additional 412,100 shares during the period. Victory Capital Management Inc. grew its stake in shares of Precision BioSciences by 121.9% during the fourth quarter. Victory Capital Management Inc. now owns 612,932 shares of the company’s stock valued at $8,514,000 after buying an additional 336,747 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Precision BioSciences by 114.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 108,226 shares of the company’s stock valued at $1,504,000 after buying an additional 57,695 shares during the last quarter. Hedge funds and other institutional investors own 49.35% of the company’s stock.

A number of research firms recently issued reports on DTIL. BidaskClub upgraded Precision BioSciences from a “sell” rating to a “hold” rating in a report on Tuesday, May 12th. ValuEngine upgraded Precision BioSciences from a “hold” rating to a “buy” rating in a research report on Wednesday, March 4th. William Blair restated a “buy” rating on shares of Precision BioSciences in a report on Monday, June 8th. HC Wainwright reaffirmed a “buy” rating and issued a $19.00 price target on shares of Precision BioSciences in a research note on Friday, June 12th. Finally, Stifel Nicolaus began coverage on shares of Precision BioSciences in a research report on Wednesday, March 4th. They issued a “buy” rating and a $21.00 price objective for the company. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Precision BioSciences currently has an average rating of “Buy” and a consensus price target of $17.44.

Shares of NASDAQ DTIL opened at $7.85 on Wednesday. The business has a fifty day moving average price of $7.65 and a 200 day moving average price of $8.55. Precision BioSciences Inc has a 1-year low of $4.60 and a 1-year high of $23.67.

Precision BioSciences (NASDAQ:DTIL) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.01. The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $5.20 million. Precision BioSciences had a negative net margin of 369.86% and a negative return on equity of 60.32%. As a group, equities analysts forecast that Precision BioSciences Inc will post -2.37 EPS for the current fiscal year.

Precision BioSciences Profile

Precision BioSciences, Inc operates as a genome editing company and develops therapeutic products in the United States. It operates through two segments, Therapeutic and Food. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities.

Further Reading: FinTech

Want to see what other hedge funds are holding DTIL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Precision BioSciences Inc (NASDAQ:DTIL).

Institutional Ownership by Quarter for Precision BioSciences (NASDAQ:DTIL)

Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.